Achieve Life Sciences, Inc. (ACHV) Stock Analysis
Healthcare · Biotechnology · NasdaqCM
Achieve Life Sciences, Inc. (ACHV) posted $0 in revenue for fiscal 2025, with a net loss of $54.65M, per its SEC filings.
Data last refreshed September 3, 2026 from SEC filings · how we compute this
The analyst's take on Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. has grown revenue from — to $0 over the last 10 fiscal years.
It carries about $14.89M of total debt.
It clears 1 of 4 deterministic health checks. The one thing worth a second look in the filings is debt with negative operating cash flow.
Synthesised from Achieve Life Sciences, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
See a claim about Achieve Life Sciences, Inc.? Check it against the filing
Open the full tool →Paste a headline number you saw about ACHV — a press-release figure, a tweet, another tool’s number — and see the filed SEC number side-by-side with its source. Free, no account.
Achieve Life Sciences, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | — | — | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-1.23M | $-10.58M | $-12.69M | $-16.39M | $-14.73M | $-33.15M | $-42.35M | $-29.82M | $-39.83M | $-54.65M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
Source: Achieve Life Sciences, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
Achieve Life Sciences, Inc. financial health: 1 of 4 checks passed
- ✗Profitable every year (last 5)
- ✓More cash than total debt (cash 36.4M vs debt 18.6M)
- ✗Positive operating cash flow (last 5 yrs)
- ✗Free cash flow positive (latest yr) (-49.5M)
Checks computed deterministically from filed annual statements — no AI judgement.
Achieve Life Sciences, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Debt with negative operating cash flowCarries $18.6M of debt while last year's operating cash flow was negative ($-49.5M).
Explore 17 years of Achieve Life Sciences, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a $24.99/month plan to track ACHV in your portfolio →
Achieve Life Sciences, Inc. financial history
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Achieve Life Sciences, Inc. — frequently asked questions
What is Achieve Life Sciences, Inc.'s revenue?
Achieve Life Sciences, Inc. (ACHV) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Achieve Life Sciences, Inc. profitable?
No — ACHV reported a net loss of $-54.65M in fiscal 2025.
How much debt does Achieve Life Sciences, Inc. have?
As of fiscal year 2025, ACHV carried roughly $14.89M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Achieve Life Sciences, Inc.'s market cap?
Achieve Life Sciences, Inc. (ACHV) has a market capitalization of about $627.25M, based on the latest data in our nightly-refreshed cache.
When does Achieve Life Sciences, Inc.'s fiscal year end?
ACHV's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Achieve Life Sciences, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.